COVID-19大流行期间急性肾损伤与体外血液净化治疗的管理:意大利SIN-SIAARTI联合调查及临床实践建议
该研究为意大利肾脏病学会(SIN)与麻醉和重症监护学会(SIAARTI)联合开展的多中心、观察性、全国在线调查,评估重症COVID-19患者AKI的发生率与管理。共收集141份回复,来自约19,000例住院COVID-19患者,其中7.3%确诊AKI,82.2%在ICU管理;仅43%的临床医生常规使用KDIGO标准。628例患者接受RRT,以连续技术最常用,少尿为最常见指征(74.05%);区域性枸橼酸抗凝最常用。41.04%的受访医生从未使用体外血液净化(EBPT)清除炎症因子或内毒素,58.54%从未使用HVHF。作者认为AKI被低估且实践差异大,需制定标准化临床指南。
要点
- 在约19,000例住院COVID-19患者中,7.3%发生确诊AKI,其中82.2%在ICU管理。
- 仅43%的临床医生常规使用国际KDIGO标准诊断AKI。
- 628例患者接受RRT,连续技术最常用,少尿为最常见指征(74.05%),早期启动更受青睐。
- 41.04%的受访医生从未使用EBPT清除炎症因子或内毒素,58.54%从未使用HVHF。
- RRT禁忌于治疗撤退或存在严重合并症或血流动力学不稳定的情况;区域性枸橼酸抗凝最常用。
适用人群与场景
- 意大利全国调查涉及的住院COVID-19患者,其中确诊AKI者82.2%在ICU管理。
- 调查对象为意大利重症监护和肾脏病领域的临床医生。
诊断标准与关键阈值
- 仅43%的临床医生常规使用国际KDIGO标准诊断AKI。
处置流程与药物剂量
- RRT在628例患者中实施,连续技术最常用,少尿为最常见指征(74.05%),早期启动更受青睐。
- RRT禁忌于治疗撤退或存在严重合并症或血流动力学不稳定的情况。
- 区域性枸橼酸抗凝是最常用的抗凝方式。
- 41.04%的受访医生从未使用EBPT清除炎症因子或内毒素;4.33%仅在存在AKI时使用,24.63%在无AKI时也使用。
- 肾脏病医生更多使用EBPT,尤其在存在AKI时。
- 58.54%的受访者从未使用HVHF,但HCO膜和吸附剂在超过50%的病例中使用。
研究设计与关键结果
- 研究类型为多中心、观察性、全国在线调查,由SIN和SIAARTI合作开展,数据收集于COVID-19大流行期间1周内。
- 共收集141份回复,54.6%来自重症监护医生,44.6%来自肾脏病医生。
- 约19,000例住院COVID-19患者中,7.3%发生确诊AKI,其中82.2%在ICU管理。
- 仅43%的临床医生常规使用KDIGO标准。
- 628例患者接受RRT,连续技术最常用,少尿为最常见指征(74.05%),早期启动更受青睐,RRT禁忌于治疗撤退或存在严重合并症或血流动力学不稳定的情况。
- 区域性枸橼酸抗凝最常用。
- 41.04%的受访医生从未使用EBPT清除炎症因子或内毒素;4.33%仅在存在AKI时使用,24.63%在无AKI时也使用。
- 肾脏病医生更多使用EBPT,尤其在存在AKI时;58.54%的受访者从未使用HVHF,但HCO膜和吸附剂在超过50%的病例中使用。
证据类型、等级与局限
- 证据类型:多中心、观察性、全国在线调查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 调查显示仅43%的临床医生常规使用KDIGO标准,提示COVID-19患者AKI诊断标准使用不足,尤其重症监护医生。
- RRT实践中心间差异大,连续技术最常用,少尿为最常见指征(74.05%),早期启动更受青睐,区域性枸橼酸抗凝最常用。
- EBPT使用差异显著:41.04%从未使用,4.33%仅在AKI时使用,24.63%在无AKI时也使用;肾脏病医生使用更多。
- 作者认为需制定标准化临床指南以规范AKI诊断和血液净化治疗。
指南或共识出处
- 意大利肾脏病学会(SIN)与麻醉和重症监护学会(SIAARTI)联合调查
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND AIM: The novel coronavirus disease 2019 remains challenging. A large number of hospitalized patients are at a high risk of developing AKI. For this reason, we conducted a nationwide survey to assess the incidence and management of AKI in critically ill patients affected by the SARS-CoV-2 infection.
METHODS: This is a multicenter, observational, nationwide online survey, involving the Italian Society of Nephrology and the critical care units in Italy, developed in partnership between the scientific societies such as SIN and SIAARTI. Invitations to participate were distributed through emails and social networks. Data were collected for a period of 1 week during the COVID-19 pandemic.
RESULTS: A total of 141 responses were collected in the SIN-SIAARTI survey: 54.6% from intensivists and 44.6% from nephrologists. About 19,000 cases of COVID-19 infection have been recorded in hospitalized patients; among these cases, 7.3% had a confirmed acute kidney injury (AKI), of which 82.2% were managed in ICUs. Only 43% of clinicians routinely used the international KDIGO criteria. Renal replacement therapy (RRT) was performed in 628 patients with continuous techniques used most frequently, and oliguria was the most common indication (74.05%). Early initiation was preferred, and RRT was contraindicated in the case of therapeutic withdrawal or in the presence of severe comorbidities or hemodynamic instability. Regional anticoagulation with citrate was the most common choice. About 41.04% of the interviewed physicians never used extracorporeal blood purification therapies (EBPTs) for inflammatory cytokine or endotoxin removal. Moreover, 4.33% of interviewed clinicians used these techniques only in the presence of AKI, whereas 24.63% adopted them even in the absence of AKI. Nephrologists made more use of EBPT, especially in the presence of AKI. HVHF was never used in 58.54% of respondents, but HCO membranes and adsorbents were used in more than 50% of cases.
CONCLUSION: This joint SIN-SIAARTI survey at the Italian Society of Nephrology and the critical care units in Italy showed that, during the COVID-19 pandemic, there was an underestimation of AKI based on the "non-use" of common diagnostic criteria, especially by intensivists. Similarly, the use of specific types of RRT and, in particular, blood purification therapies for immune modulation and organ support strongly differed between centers, suggesting the need for the development of standardized clinical guidelines.
参考来源
- De Rosa S, Marengo M, Romagnoli S, et al. Management of Acute Kidney Injury and Extracorporeal Blood Purification Therapies During the COVID-19 Pandemic: The Italian SIN-SIAARTI Joint Survey (and Recommendations for Clinical Practice). Front Med (Lausanne). 2022. PMID: 35463000. doi:10.3389/fmed.2022.850535
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。